Skip to content

The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis

The Efficacy and Safety of 2.5 mg Chlorhexidine Gluconate Chip (PerioChip®) in Frequent Treatment Versus Routine Treatment in Therapy of Adult Chronic Periodontitis

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01249846
Enrollment
Unknown
Registered
2010-11-30
Start date
2010-12-31
Completion date
Unknown
Last updated
2013-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Generalized Adult Periodontitis

Brief summary

The purpose of this study is to assess the efficacy and the safety of Chlorhexidine Gluconate Chip (PerioChip®) in frequent treatment versus routine treatment in therapy of adult chronic periodontitis.

Interventions

DRUGPerioChip ®

Sponsors

Dexcel Pharma Technologies Ltd.
Lead SponsorINDUSTRY

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Signed and dated Informed Consent Form. 2. Good general health. 3. Male or female patients aged \>21 years old. 4. Availability for the 25 week duration of the study. 5. Chronic periodontal disease on natural teeth 6. Females of childbearing potential must be non-pregnant and non-lactating at entry and agree to use an adequate method of birth control during the study.

Exclusion criteria

1. Oral health or factor that may influence the outcome of the study. 2. History of allergy to Chlorhexidine . 3. Patient uses Chlorhexidine oral rinses/mouthwashes on a regular basis. 4. Patients treated with medications that may influence the outcome of the study. 5. Presence of any of the following conditions: Type 1 diabetes, un-controlled type II diabetes, major recurrent aphtae stomatitis, abscesses and related oral pathologies. 6. The presence of any medical or psychiatric condition or any other condition that, in the opinion of the Investigator, could affect the successful participation of the patient in the study. 7. Patient participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026